Akarna Therapeutics Secures $15,000,000 Series B Round

  • Feed Type
  • Date
    2/17/2016
  • Company Name
    Akarna Therapeutics
  • Mailing Address
    1012 Second Street Encinitas, CA 92007 USA
  • Company Description
    Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment.
  • Website
    http://www.akarna.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies.
  • M&A Terms
  • Venture Investor
    Forbion Capital Partners
  • Venture Investor
    New Science Ventures
  • Venture Investor
    Third Point

Trending on Xconomy